<?xml version="1.0" encoding="UTF-8"?>
<p id="Par14">The prevalence in tuberculosis (TB), together with the recent increase in the incidence of multidrug-resistance (MDR) cases, has led to the search for new drug targets and new drugs that are effective against Mtb. TB is often a fatal disease, and one that poses a global threat to human health [
 <xref ref-type="bibr" rid="CR5">5</xref>, 
 <xref ref-type="bibr" rid="CR6">6</xref>]. Globally, infection associated with TB is second only to HIV/AIDS as the greatest killer due to a single initiating infectious agent [
 <xref ref-type="bibr" rid="CR25">25</xref>]. Out of the 9 million people infected with TB in a year, 3 million are left untreated, acting as a reservoir for further infection. Many of these 3 million untreated cases live in poverty with minimal access to healthcare. Over 95% of TB cases and deaths are in developing countries such as South Africa, often where the percentage of HIV/AIDS co-infection is high, and therefore occurs in individuals with compromised immune systems (WHO, 2020) [
 <xref ref-type="bibr" rid="CR25">25</xref>].
</p>
